Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspira Womens HealthAWHL -8.82%38 Debt-to-Equity is -0.69 as of Mar. 2026. GuruFocus rates AWHL with a GF Score™ of 38/100 and a GF Value™ of $0.27 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 181 Medical Diagnostics & Research companies, Aspira Womens Health ranks worse than 552485.64% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Aspira Womens Health's Debt-to-Equity or its related term are showing as below:
AWHL'
s Debt-to-Equity Range Over the Past 10 Years
Min: -50.93 Med: 0.17 Max: 4.25
Current: -0.69
During the past 13 years, the highest Debt-to-Equity Ratio of Aspira Womens Health was 4.25. The lowest was -50.93. And the median was 0.17.
AWHL's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.31
vs AWHL: -0.69
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Aspira Womens Health Debt-to-Equity Related Terms
Aspira Womens Health Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Aspira Womens Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AWHL vs MDXH, QUCY, XWEL: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Aspira Womens Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (AWHL) has a Debt-to-Equity of -0.69 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Aspira Womens Health and its competitors. According to the industry distribution chart, Aspira Womens Health ranks #999999 out of 181 companies in the Medical Diagnostics & Research industry.
Is Aspira Womens Health's Debt-to-Equity too high?
Aspira Womens Health's current Debt-to-Equity is -0.69. Based on the distribution chart, Aspira Womens Health ranks #999999 out of 181 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Aspira Womens Health has a GF Score™ of 38/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's Debt-to-Equity compare to MDXH and QUCY?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #999999 out of 181 companies for Debt-to-Equity. This places Aspira Womens Health in the lower half of its industry. The industry median Debt-to-Equity is 0.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.31, based on 181 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Aspira Womens Health and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Womens Health's current Debt-to-Equity is -0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $0.31 — trading 14.8% above its estimated fair value. The current Debt-to-Equity is -0.69. Aspira Womens Health's overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current Debt-to-Equity is -0.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Womens Health (AWHL) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued.
The current stock price of $0.31 is trading 14.8% above its estimated GF Value™ of $0.27.
GuruFocus considers Aspira Womens Health to be Modestly Overvalued.
Key valuation signals for AWHL:
Debt-to-Equity: -0.69
GF Value™: $0.27 vs. price of $0.31 (14.8% above fair value)
No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
38GF Score
Get the complete analysis for AWHL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AWHL has been successfully added to your 
